Press-release for stocks related to genetown

Prices are updated after-hours

for tags : Genetown

save search

Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
BPMC | $85.18 -2.37% -2.42% 510K

Health Technology

| -5.87% | O: 1.08% H: 1.19% C: 0.85%
conference for therapeutics

Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
CRL | $235.93 -2.24% 0.0% 460K

Commercial Services

| -4.67% | O: 0.48% H: 0.0% C: 0.0%
for

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
MCRB | $0.6179 -5.62% -5.7% 3.8M

Health Technology

| -16.16% | O: -2.31% H: 3.86% C: -1.47%
ser-155 for trial therapeutics

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
SYRS | $5.35 -0.74% -1.32% 150K

Health Technology

| 15.3% | O: 2.16% H: 23.21% C: 16.03%
fda treatment designation for aml

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor
Published: 2024-04-08 (Crawled : 14:00) - biospace.com/
CCCC | $6.86 -7.42% -8.02% 1.7M

Health Technology

| -10.44% | O: -1.57% H: 0.0% C: 0.0%
cft1946 approved preclinical for therapeutics

Haemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge
Published: 2024-04-04 (Crawled : 11:00) - biospace.com/
HAE | $84.88 -0.4% 0.0% 320K

Health Technology

| 0.22% | O: 0.05% H: 1.54% C: 0.19%
teg fda clearance global

Hologic to Announce Financial Results for the Second Quarter of Fiscal 2024 on Thursday, May 2, 2024
Published: 2024-04-02 (Crawled : 14:30) - biospace.com/
HOLX | $77.54 0.27% 0.3% 1.6M

Health Technology

| 1.87% | O: 0.0% H: 0.12% C: -0.05%
financial results

Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
Published: 2024-03-25 (Crawled : 23:00) - biospace.com/
STOK | $12.21 -4.39% -4.33% 2.4M

Health Technology

| 93.81% | O: -0.16% H: 8.11% C: 3.34%
stk-001 first treatment therapeutics potential

Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2024-03-21 (Crawled : 21:00) - biospace.com/
VRTX | $397.36 0.2% 0.23% 1.1M

Health Technology

| -3.58% | O: 0.85% H: 0.88% C: 0.02%
vx-407 fda drug disease kidney treatment clearance application

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease
Published: 2024-03-19 (Crawled : 12:00) - biospace.com/
ENVB | $0.9215 -8.76% -7.45% 160K

Health Technology

| -16.23% | O: 54.55% H: 10.0% C: -30.0%
disease

FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
Published: 2024-03-15 (Crawled : 23:00) - biospace.com/
TSVT | $4.985 -1.09% -1.1% 330K

| 25.88% | O: 2.27% H: 8.4% C: -0.99%
BMY | $48.51 0.48% 0.19% 9.8M

Health Technology

| -7.58% | O: -0.32% H: 1.67% C: 0.04%
fda therapy

bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
Published: 2024-03-11 (Crawled : 17:00) - biospace.com/
BLUE | $1.03 -6.36% -6.28% 6.2M

Health Technology

| -31.33% | O: 7.33% H: 3.1% C: -13.66%
first disease cell agreement therapy

BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: 2024-03-07 (Crawled : 23:00) - biospace.com/
BGNE S | $138.4 -2.05% -2.1% 210K

Health Technology

| -13.24% | O: -0.93% H: 3.2% C: 2.66%
fda brukinsa approval treatment

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting
Published: 2024-03-06 (Crawled : 14:30) - biospace.com/
HBIO | $4.44 4.72% 3.64% 190K

Health Technology

| 5.97% | O: 1.67% H: 3.48% C: -3.52%
bioscience preclinical solutions meeting

Valo Health Completes Enrollment of OPL-0401 Phase 2 Study for the Treatment of Diabetic Retinopathy
Published: 2024-03-04 (Crawled : 18:00) - biospace.com/
SNYNF | $92.966 0.07% -2.18% 630

Health Technology

| -1.62% | O: -0.9% H: 0.0% C: 0.0%
SNY | $46.24 0.68% 0.63% 1.6M

Health Technology

| -1.08% | O: -0.8% H: 0.0% C: 0.0%
opl-0401 health treatment study diabetic

Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease
Published: 2024-03-04 (Crawled : 16:00) - biospace.com/
QTRX | $17.15 -6.64% -6.8% 660K

Health Technology

| -36.48% | O: 3.7% H: 1.64% C: 0.25%
fda device disease test granted alzheimer’s designation

Boston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon
Published: 2024-03-01 (Crawled : 15:30) - biospace.com/
BSX | $67.44 -0.93% -0.5% 5.2M

Health Technology

| 1.86% | O: 0.21% H: 1.58% C: 1.18%
fda approval

Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023
Published: 2024-02-29 (Crawled : 23:00) - biospace.com/
QTRX | $17.15 -6.64% -6.8% 660K

Health Technology

| -26.96% | O: 1.66% H: 2.37% C: 0.38%
year results

Novanta Announces Financial Results for the Fourth Quarter and Full Year 2023
Published: 2024-02-28 (Crawled : 13:00) - biospace.com/
NOVT | $161.18 -1.12% -1.17% 140K

Electronic Technology

| 2.46% | O: 0.69% H: 6.25% C: 5.71%
year financial results

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
Published: 2024-02-27 (Crawled : 13:00) - biospace.com/
NUVL | $65.28 -0.35% -0.38% 520K